前列腺癌的治疗(6)
巴细胞为正性刺激，而CTLA-4则为负性刺激，使用CTLA-4抗体消除CTLA-4的负性作用同可加强T细胞的免疫功能，使鼠体中的肿瘤消失[29]。
CD4T细胞又称T辅助细胞(Th)，Th细胞可分为Th1及Th2两大类，Th1参与人体的细胞免疫，Th2同负责人体的体液免疫。1L-12，1L-15，CD28均可加强Th1的免疫功能。CTL及Th1细胞主要通过两种途径使肿瘤细胞凋亡，CTL细胞与靶细胞接触后，分泌穿孔素及Granzyme A与Granzyme B蛋白分解酶，穿孔素将靶细胞膜窕透后，注入Granzyme而使细胞凋亡，另一途径则为CTL及CD4产生的细胞表面蛋白死亡因子Fasl，它与靶细胞上的死亡因子受体(FasR)结合后可使细胞死亡[30]。
这些实验性的研究工作具体对前列腺癌的意义如何，则尚待进一步深入的了解。
References
1. Rose MA. Impact of prostatic specific antigen screening on the natural history of prostatic cancer. Urol, 1995, 46:757.
2. Catalona WJ. Management of cancer of the prostate. N Eng J Med, 1994, 331:996.
3. Hands GE,Meyers CE,Scarduno PT.Cancer of the prostate. Cancer Principle and practice of Oncology, 4th Ed, 1993, P1073, Edited by Vincent J, De Vita Jr, JB Lippincott Comp.
4. Y Wang. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low fat diet. JNCI, 1995, 87:1456.
5. Ross RK, Pike MC, Berstein L. et al. 5α-reductase activety and risk of prostate cancer among Japanese and US white and black males. The Lancet, 192, 339:887.
6. Geller J. Approach to chemoprevention of prostate cancer. J Clin Endocrin & Met, 1995,80:717.
7. Coetzee GA, Ross RK. Prostatic cancer and the androgen receptor. JNCI, 1994, 86:872.
8. Thdahash H, Furusato M, Boyd J et al. Prevalence of androgen receptor gene mutation in latent prostatic carcinoma form Japanese man. Man Res. 1995, 55：1621。
9. Oesterling JE， Suman VJ，Zincke H, et al. PSA-Ketected (Clinical Stage Tlc or BO) prostate Cancer. Urol Clin North Am, 1993, 20:681.
10. Hemphrey PA, Smith DS, Catalona WJ. Prospective characterization of pathological feature of prostatic carcinoma detected via serum PSA-based screening. J Urol, 1996, 155:816.
11. Hankes GE. Treatment of early stage prostate cancer: Radiotherapy. Important advances in Oncology. 1994, Edited by Vincent J Jr. P. 225, JB Lippincott Comp., http://www.100md.com(鲍镇美)
CD4T细胞又称T辅助细胞(Th)，Th细胞可分为Th1及Th2两大类，Th1参与人体的细胞免疫，Th2同负责人体的体液免疫。1L-12，1L-15，CD28均可加强Th1的免疫功能。CTL及Th1细胞主要通过两种途径使肿瘤细胞凋亡，CTL细胞与靶细胞接触后，分泌穿孔素及Granzyme A与Granzyme B蛋白分解酶，穿孔素将靶细胞膜窕透后，注入Granzyme而使细胞凋亡，另一途径则为CTL及CD4产生的细胞表面蛋白死亡因子Fasl，它与靶细胞上的死亡因子受体(FasR)结合后可使细胞死亡[30]。
这些实验性的研究工作具体对前列腺癌的意义如何，则尚待进一步深入的了解。
References
1. Rose MA. Impact of prostatic specific antigen screening on the natural history of prostatic cancer. Urol, 1995, 46:757.
2. Catalona WJ. Management of cancer of the prostate. N Eng J Med, 1994, 331:996.
3. Hands GE,Meyers CE,Scarduno PT.Cancer of the prostate. Cancer Principle and practice of Oncology, 4th Ed, 1993, P1073, Edited by Vincent J, De Vita Jr, JB Lippincott Comp.
4. Y Wang. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low fat diet. JNCI, 1995, 87:1456.
5. Ross RK, Pike MC, Berstein L. et al. 5α-reductase activety and risk of prostate cancer among Japanese and US white and black males. The Lancet, 192, 339:887.
6. Geller J. Approach to chemoprevention of prostate cancer. J Clin Endocrin & Met, 1995,80:717.
7. Coetzee GA, Ross RK. Prostatic cancer and the androgen receptor. JNCI, 1994, 86:872.
8. Thdahash H, Furusato M, Boyd J et al. Prevalence of androgen receptor gene mutation in latent prostatic carcinoma form Japanese man. Man Res. 1995, 55：1621。
9. Oesterling JE， Suman VJ，Zincke H, et al. PSA-Ketected (Clinical Stage Tlc or BO) prostate Cancer. Urol Clin North Am, 1993, 20:681.
10. Hemphrey PA, Smith DS, Catalona WJ. Prospective characterization of pathological feature of prostatic carcinoma detected via serum PSA-based screening. J Urol, 1996, 155:816.
11. Hankes GE. Treatment of early stage prostate cancer: Radiotherapy. Important advances in Oncology. 1994, Edited by Vincent J Jr. P. 225, JB Lippincott Comp., http://www.100md.com(鲍镇美)